Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Receivables (2016 - 2025)

Historic Receivables for Arrowhead Pharmaceuticals (ARWR) over the last 14 years, with Q4 2025 value amounting to $228.7 million.

  • Arrowhead Pharmaceuticals' Receivables rose 904792.0% to $228.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $228.7 million, marking a year-over-year increase of 904792.0%. This contributed to the annual value of $6.8 million for FY2025, which is N/A changed from last year.
  • Arrowhead Pharmaceuticals' Receivables amounted to $228.7 million in Q4 2025, which was up 904792.0% from $6.8 million recorded in Q3 2025.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Receivables peaked at $228.7 million during Q4 2025, and registered a low of $239000.0 during Q2 2022.
  • Its 5-year average for Receivables is $28.0 million, with a median of $3.0 million in 2023.
  • Its Receivables has fluctuated over the past 5 years, first plummeted by 9854.67% in 2021, then surged by 2572720.0% in 2022.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Receivables (Quarter) stood at $250000.0 in 2021, then surged by 25727.2% to $64.6 million in 2022, then crashed by 95.29% to $3.0 million in 2023, then decreased by 17.74% to $2.5 million in 2024, then skyrocketed by 9047.92% to $228.7 million in 2025.
  • Its Receivables stands at $228.7 million for Q4 2025, versus $6.8 million for Q3 2025 and $9.7 million for Q2 2025.